This ‘win-win’ hedge trade is getting popular with traders

A trader works on the floor of the American Stock Exchange AMEX) at the New York Stock Exchange (NYSE) in New York, US, on Wednesday, May 6, 2026.

Michael Nagle | Bloomberg | Getty Images

Aggressive options trading in the semiconductor stocks is creating a volatility spread that’s being used by traders to stay bullish in the sector that’s rallying the most, while simultaneously hedging risks in the broader market.

The trade is fairly simple: sell downside protection in semiconductor names where volatility is expensive, and buy downside protection in the S&P 500, where it’s relatively cheap, with VIX this week touching the lowest levels in three months.

Here’s why it’s uniquely compelling at this juncture.

Implied volatility in the VanEck Semiconductor ETF (SMH) is 46, more than 2.5 times that of the S&P 500, where the Cboe Volatility index (VIX) trades around 17. Oftentimes volatility moves down as stocks grind higher, but in the case of chips, where prices are moving parabolic, volatility is rising alongside prices.

Stock Chart IconStock chart icon

VanEck Semiconductor ETF, YTD

As a result, traders are shifting some of that call-buying appetite in SMH towards selling of puts instead: on Wednesday, more than 5x more puts were sold versus calls bought. It’s still a bullish view on the sector, but more specifically targeting the rich premiums of the options.

The second part of the trade is to use that income to go long volatility in the S&P 500 via index puts or VIX calls.

‘Win-win’

If chips go up, you keep the net credit. If chips go down, the stock market most likely will too, and the S&P puts will pay off. Plus, there’s a bonus kicker to the trade: Because volatility in chips has risen with their price, it’s possible volatility could come down even if the group sells off – giving traders even more cushion on the puts they sold.

Stock Chart IconStock chart icon

hide content

S&P 500, YTD

“The premium you’re harvesting selling the puts will far outpace what you’d lose on the index because even if the market grinds higher, those S&P puts aren’t going to lose a lot of value,” said Scott Bauer, CEO of Chicago-based Prosper Trading Academy. “It’s massive vol skew and if there is a pull back in semis, it gives you the opportunity to reload at a lower price, whereas selling calls could be a career-ending trade. It absolutely can be a win-win.”

Wednesday’s intraday action offered a prime example of how both trades can win at once. Semiconductors and VIX both hit their lows around 9:20 am CT, then both rallied into the bell

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

Source link

Visited 1 times, 1 visit(s) today

Related Article

5 Oversold AI Stocks: Where Wall Street Analysts Are Spotting 50%+ Upside

The AI selloff has opened a wide gap between share prices and Wall Street’s expectations. Some of the stocks below have lost nearly half their value in 30 days, while their average analyst targets still imply gains well above 50%. It sounds like an opportunity but can also mean the market has moved faster than

Is Nike Still a Growth Stock? Here’s the Answer.

By now, Nike (NYSE: NKE) shareholders are well aware that the company’s fiscal 2027 could be a tough stretch. In the company’s 2027 first-quarter earnings report, revenue fell 4% year over year to $11.2 billion, and net income slid 2% to $712 million. The athletic wear giant has been in the midst of a turnaround

Jim Cramer’s Case for “Accidental High Yielders” When the Fed Shakes the Market

Quick Read Verizon’s 6.3% yield is backed by strong coverage, with dividends consuming only 57% of EPS guidance and 58% of first-half free cash flow. T. Rowe Price’s quarterly dividend grew from $1.24 to $1.30 while its share price fell 37%, but $56.9 billion in 2025 client outflows signal real business damage. Cramer calls accidental

Verizon (VZ) Stock Looks Reasonable After A 62% Three Year Gain

Verizon Communications has delivered a strong multi year share price gain, leaving investors asking whether the current US$44.66 stock price is fully supported by the earnings the business is generating today. Over the past 3 years the stock has returned 62.4%, which puts more weight on the question of how closely its market value now

Can GigaCloud Technology (GCT) Stay Below Fair Value On Cash Flow?

GigaCloud Technology has delivered a very strong share price run in recent years, which naturally raises a question for anyone looking at the stock today. Are the cash flows behind GigaCloud Technology robust enough, and predictable enough, to support where the share price now trades? Over the past 3 years, GigaCloud Technology has produced a

Is MP Materials Stock a Millionaire Maker?

MP Materials (NYSE: MP) has ample long-term growth potential, but can it become a “millionaire maker?” Trading at a nearly $7 billion valuation, the company has grown very far, very fast, making it questionable whether a small investment can grow into a $1 million position. Yet while MP Materials stock may not make you a

Caterpillar Is Quietly Becoming an AI Stock. Here’s the Segment Growing 72% That Proves It.

When most people think of Caterpillar (NYSE: CAT), they think of the iconic yellow tractors, harvesters, and other farm equipment that have powered American agriculture for over a century. And of course, the company is also known for its construction equipment, including backhoes, bulldozers, and excavators (also yellow), among many other types of heavy equipment.

Applied Materials Sinks 17% in a Week After a Forecast-Free Investor Day: “Tremendous Confidence”

Applied Materials Sinks 17% in a Week After a Forecast-Free Investor Day: “Tremendous Confidence” ©@Kittipong Jirasukhanont from PhonlamaiPhoto’s Images via Canva, @Iulian Catalin’s Images via Canva Key Takeaways Applied Materials stock has declined 24% since October 12, including a 6.7% drop following its October 13 investor presentation. Management outlined ambitious 2030 profitability targets but declined

What Will a $10,000 Investment in Palantir Be Worth by 2030?

Palantir (NASDAQ: PLTR) investors have had a fairly rocky 2026. For most of the year, the stock was losing money. However, starting in August, Palantir reversed the decline and has now gained about 12% for the year. That is roughly in line with the gain for the S&P 500 (SNPINDEX: ^GSPC). However, if you survey

3 Reasons to sell NEOG and 1 stock to buy instead

3 Reasons to sell NEOG and 1 stock to buy instead Neogen’s 25.9% return over the past six months has outpaced the S&P 500 by 16.8%, and its stock price has climbed to $11.78 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

3 Oil Stocks With Earnings Growth Over 5%

Oil just hit a five month high as supply risks from the Middle East and attacks on key energy facilities push energy markets back into the spotlight. When crude prices get this much attention, the largest integrated producers and pipeline giants can draw fresh investor interest. This article walks through three leading global oil and

Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.

The AI trade has looked awfully shaky over the last couple of weeks. CoreWeave, the neocloud company that may have more leveraged exposure to AI than any other company due to its massive debt burden, has plunged in recent weeks on fears over its rising debt yields. Missed AI’s “Act 1”? Act 2 Could Be

Hormel (HRL) Stock Looks Reasonably Priced As Earnings Stay Steady

Hormel Foods has seen its share price slide over the past few years, and that drop puts a spotlight on a simple question for investors who focus on fundamentals. Is the current valuation of Hormel stock still in line with the earnings power the business is producing today? Over the past 5 years, the share

Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own

Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for the next breakthrough.

0
Would love your thoughts, please comment.x
()
x